RIGL News

Rigel (RIGL) delivered earnings and revenue surprises of -25.29% and +3.35%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Rigel Reports Third Quarter 2026 Financial Results Rigel Reports Third Quarter 2026 Financial ResultsPR NewswireSOUTH SAN FRANCISCO, Calif., Nov. 5, 2026 Third quarter 2026 total revenues of $80.9 million, including net product sales of $72.3 million and contract revenues from collaborations of...

Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology...

United Therapeutics (UTHR) delivered earnings and revenue surprises of -2.39% and +6.28%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial ResultsPR NewswireSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel...

Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026PR NewswireSOUTH SAN...

ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR NewswireSOUTH SAN FRANCISCO, Calif., Oct. 2, 2026SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire...

A large exercise of company stock options by Dean Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals (NASDAQ:RIGL) was disclosed in a new SEC filing on September 3, as part of an insider exercise. Whatread more...